UEG Week 2025: Relive the Highlights

From groundbreaking research to expert debate — experience it all again on demand. Recordings and posters now available on gutflix.eu

Explore your recommendations now!

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Podcast Episode

Journal Podcast

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Autoimmune pancreatitis and inflammatory bowel disease

Iago Rodríguez-Lago 1, Miroslav Vujasinovic 2

1 Hospital Universitario de Galdakao, Bilbao, Spain

2 Karolinska University Hospital, Stockholm, Sweden

Topics

IBD

Published

2022

UEG Podcast Episode

UEG Podcast

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Raising pancreatic superstars: from mice to knives

Egle Dieninyte - Misiune 1, Johanna Laukkarinen 2, Alberto Balduzzi 3

1 Center of hepatology, gastroenterology and dietetics, Vilnius university Santaros Klinikos, Lithuania

2 Tampere University Hospital, Tampere, Finland

3 Hospital P. Pederzoli, Peschiera del Garda, Verona, Italy

Topics

Pancreas

Published

2024

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Panel discussion: Liver and pregnancy - Beware of dangerous liaisons

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Hepatobiliary Paediatrics

Session

Liver and pregnancy: Beware of dangerous liaisons

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

The management of acute pancreatitis

Georg Beyer 1

1 University Hospital LMU Munich, München, Germany

Event

UEG Week Berlin 2025

Topics

Hepatobiliary Nurses Small Intestine & Nutrition Pancreas

Session

Mistakes in …: Hepatobiliary and pancreas

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

MAGNETIC RESONANCE IMAGING (MRI) SHOWS CHANGES IN BOWEL MORPHOLOGY AND MOTILITY IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) AND COLON-IN-CONTINUITY (CIC) AFTER TREATMENT WITH THE LONG-ACTING GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOG APRAGLUTIDE

Not sure what you can access? Learn more about account types.

Introduction

SBS-IF is a severe organ failure with long-term parenteral support (PS) dependence. In the first years after extensive surgery, spontaneous structural (elongation of intestinal villi and crypts) and functional (incl. motility) intestinal changes occur, stimulating a more efficient nutrient and fluid absorption in the remnant bowel. GLP-2 analogs are hypothesized to boost intestinal adaptation resulting in increased intestinal absorption and reduced PS needs. Apraglutide (APRA) is a long-acting GLP-2 analog in development for SBS-IF. We investigated the effect of APRA at 52 weeks (W) on bowel morphology and motility based on magnetic resonance imaging (MRI).

Aims & Methods

STARS Nutrition is a 52-W multicenter, open-label, phase 2 study in adult SBS-IF-CiC pts receiving weekly subcutaneous APRA injections (5mg). We hypothesized that APRA treatment would lead to thickening of the intestinal mucosa, intestinal lengthening, reduced bowel dilatation and reduced intestinal motility. Therefore, MRI scans of the abdomen, incl. cine sequences, after oral intake of a mannitol solution (600mL) were performed at baseline and at 4W, 24W and 48W of treatment. Morphology parameters were measured on static MRI sequences; GI Quant software was used to quantify motility on cine MRI sequences. Data are presented as median (IQR). Nominal p-values are calculated using Wilcoxon matched-pairs signed rank tests with significance set at 0.05.

Results

Nine pts were included and comprise the full study population. While the numerically increased colon length failed to reach significance, small bowel length increased significantly from 29.7 to 40.7 cm (p=0.012) at 48W. Duodenal wall thickness increased by 0.8 (0.2;1.2) mm (p=0.020). There were no diameter changes in the small bowel nor colon. Changes in motility were evaluated using data from 7 pts, due to missing data. Over time, small bowel motility gradually reduced, albeit not significant. Motility in the proximal colon was significantly reduced at 48W. In the distal colon, decreased motility was observed at 4W and 24W, but returned to baseline level at 48W.

Conclusion

Using static and cine MRI sequences in pts with SBS-IF-CIC, STARS Nutrition shows that APRA treatment was associated with small bowel lengthening and increased duodenal wall thickness suggesting an intestinotrophic effect. Both effects may contribute to an increased surface area for absorption. The reduced motility, especially in the proximal colon may reduce transit time, allowing more time for absorption of nutrients, fluids and electrolytes; and reduced fecal output. Whether bowel lengthening results from a direct effect of APRA vs. changes in motility with passive elongation is subject of further investigation.

Disclosure

Astrid Verbiest, Mark Krogh Hvistendahl, Ragna Vanslembrouck, Ronald Peeters, Riccardo Sartoris – nothing to declare.
Palle Bekker Jeppesen – received grants/research support/honoraria or consultation fees from Agomab, Albumedix A/S, ArTara Therapeutics, Bainan Biotech, Baxter, Coloplast, Ferring, Fresenius Kabi, GLyPharma, Naia Pharma, NPS Pharmaceuticals, NorthSea Therapeutics, Shire, Takeda, The Novo Nordisk Foundation, Therachon, VectivBio and Zealand Pharma.
Francisca Joly – has received grants/research support/honoraria or consultation fees from Agomab, Baxter, Fresenius Kabi, Nestlé Health Sciences, BBraun, Theradial, Mayoli, Biocodex, mobile3e Consulting, Carembouche, NPS Pharmaceuticals, NorthSea Therapeutics, Shire, Takeda, Therachon, VectivBio and Zealand Pharma.
Tim Vanuytsel – has served on the speaker bureau for Abbott, Agomab, Baxter, Biocodex, Dr. Falk Pharma, Fresenius Kabi, Ipsen, Menarini, Microbiotica, MyHealth, Remedus, Takeda, Truvion, VectivBio and Zealand Pharma. TV has provided clinical advice to Baxter, Danone, Dr. Falk Pharma, MyHealth, NorthSea Therapeutics, Shire, Therachon, Takeda, VectivBio, Zealand Pharma. TV has received research grants from Danone, MyHealth, Takeda and VectivBio.
Federico Bolognani, Carrie Li and Nader N. Youssef – employees of VectivBio/Ironwood.

This research was supported by VectivBio AG/Ironwood.

MAGNETIC RESONANCE IMAGING (MRI) SHOWS CHANGES IN BOWEL MORPHOLOGY AND MOTILITY IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) AND COLON-IN-CONTINUITY (CIC) AFTER TREATMENT WITH THE LONG-ACTING GLUCAGON-LIKE PEPTIDE-2 (GLP-2) ANALOG APRAGLUTIDE

Astrid Verbiest 1, Alex Menys 2, Ragna Vanslembrouck 3, Ronald Peeters 3, Riccardo Sartoris 4, Mark Krogh Hvistendahl 5, Federico Bolognani 6, Carrie Li 6, Nader N. Youssef 6, Palle Bekker Jeppesen 5, Francisca Joly 4, Tim Vanuytsel 1

1 University of Leuven, Leuven, Belgium|||University Hospitals Leuven, Leuven, Belgium

2 Motilent, London, United Kingdom

3 University Hospitals Leuven, Leuven, Belgium

4 Hôpital Beaujon, Clichy, France

5 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

6 VectivBio/Ironwood, Basel, Switzerland

Event

UEG Week Vienna 2024

Topics

Mechanisms & Personalised Medicine Neurogastroenterology & Motility Radiology & Imaging Small Intestine & Nutrition

Submission format

Abstract

Session

Short bowel syndrome

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Poster

Audio / Video Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Atrophic gastritis (AG) is a well-established precursor of gastric cancer, and its most frequent aetiological agent is Helicobacter pylori (H. pylori). Accurate risk stratification is essential to optimise endoscopic surveillance and resource allocation. The Operative Link on Gastritis Assessment (OLGA) system offers a histological staging tool to quantify the severity of gastric atrophy and associated cancer risk. Despite high H. pylori endemicity in Colombia, local data on the prevalence of advanced OLGA stages remains scarce. This study aimed to elucidate the distribution of OLGA stages and their correlation with age and H. pylori status in a large dyspeptic cohort.

Aims & Methods

We conducted a cross-sectional, observational study of adult patients undergoing upper gastrointestinal endoscopy for dyspepsia between January 2019 and December 2023 at a high-volume reference centre in Bogotá, Colombia. All cases followed the updated Sydney biopsy protocol, with five mapped gastric samples analysed by experienced gastrointestinal pathologists. The OLGA system was applied to stage gastric atrophy (0–IV). H. pylori detection was based on histology using Giemsa and H&E stains. Demographic variables, H. pylori status, OLGA stage, and histological features were recorded. Data were processed using SPSS v26, and statistical significance was set at p<0.05.

Results

Out of 6,746 patients (mean age: 59 years; 73.4% female), 99% exhibited low-risk OLGA stages (0–II). Only 3 patients (0.04%) presented with advanced OLGA stages (III–IV). A positive correlation was noted between increasing age and the frequency of gastric atrophy, although this did not correspond to an increase in advanced stages. H. pylori infection was confirmed in 82% of the cohort, showing an upward trend over the study period. Interestingly, no cases of H. pylori infection were observed among patients with OLGA III–IV. The majority of infections were restricted to the antrum. Gastric dysplasia and cancer were rare events, both observed in <1% of patients. The association between H. pylori and gastric cancer did not reach statistical significance (OR 0.49; 95% CI 0.23–1.04; p=0.07).

Conclusion

Despite the high prevalence of H. pylori, the frequency of advanced OLGA stages remains remarkably low in Colombian dyspeptic patients. These findings reinforce the utility of the OLGA system, coupled with Sydney protocol biopsies, as a valuable approach to risk stratification. Only 1% of patients would benefit from endoscopic surveillance under international guidelines, suggesting that widespread follow-up may be unnecessary and potentially wasteful.

References

1. Rugge M, Genta RM, Dixon MF. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008 Oct;40(10):650–8. doi:10.1016/j.dld.2008.02.029.
2. El-Zimaity HM, Graham DY. Evaluation of gastric mucosal atrophy in clinical practice: OLGA is OK, but incomplete and in need of standardization. Am J Gastroenterol. 2011 Feb;106(2):469–70. doi:10.1038/ajg.2010.417.
3. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992 Dec 1;52(24):6735–40.
4. Herrera-Goossens A, Bravo LE, Correa P. Helicobacter pylori infection and histopathological findings in a population at high risk for gastric cancer in Colombia. Am J Gastroenterol. 2005 Nov;100(11):2314–20. doi:10.1111/j.1572-0241.2005.00226.x.